GSK221530
Trial Overview
Official Title
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Study Purpose
To evaluate the efficacy of dostarlimab as sequential therapy following CRT as compared to placebo in participants with PD-L1 positive LA unresected HNSCC
Diagnosis
Newly diagnosed unresected locally advanced head and neck squamous cell carcinoma (Stages III-IVB)Eligibility
Newly diagnosed unresected locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and completed cisplatin plus radiotherapy, and has no evidence of distant metastatic disease.
Intervention
Dostarlimab vs. Placebo
For more information, go to the link below:
https://clinicaltrials.gov/study/NCT06256588?term=221530&rank=1
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 years and older
Enrollment Status
Pending
Phase
Phase III
Methodist Health System Trial Code
GSK221530